Becton, Dickinson and Company (LON:0R19)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 51.66B |
| Revenue (ttm) | 16.49B |
| Net Income (ttm) | 1.38B |
| Shares Out | n/a |
| EPS (ttm) | 4.75 |
| PE Ratio | 37.45 |
| Forward PE | n/a |
| Dividend | 3.03 (1.34%) |
| Ex-Dividend Date | Mar 10, 2025 |
| Volume | 1,008 |
| Average Volume | 1,285 |
| Open | 227.74 |
| Previous Close | 225.99 |
| Day's Range | 226.30 - 228.10 |
| 52-Week Range | 226.30 - 286.33 |
| Beta | 0.43 |
| RSI | 40.72 |
| Earnings Date | Feb 6, 2025 |
About LON:0R19
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system... [Read more]
Financial Performance
In 2024, LON:0R19's revenue was $20.18 billion, an increase of 4.16% compared to the previous year's $19.37 billion. Earnings were $1.71 billion, an increase of 19.73%.
Financial numbers in USD Financial StatementsNews
BD to Present at Investor Healthcare Conferences
FRANKLIN LAKES, N.J. , Feb. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following ...
Insider Sell: Bertram Scott Sells Shares of Becton Dickinson & Co (BDX)
Insider Sell: Bertram Scott Sells Shares of Becton Dickinson & Co (BDX)
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit
Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.
BD (BDX) Stock Drops Amid Market Volatility and Strong Financials
BD (BDX) Stock Drops Amid Market Volatility and Strong Financials
Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business
Becton Dickinson to Separate Biosciences and Diagnostic Solutions Business
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
On Wednesday, Becton, Dickinson and Company (NYSE: BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and ...
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
On Wednesday, Becton, Dickinson and Company BDX authorized to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus, and growth-or...
Becton, Dickinson and Company 2025 Q1 - Results - Earnings Call Presentation
Becton, Dickinson confirms plans to separate life sciences business
Becton, Dickinson plans to separate its Biosciences and Diagnostic Solutions business, aiming to unlock value and accelerate innovation in MedTech. Read more here.
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Becton Dickinson looks to separate life sciences unit
Becton Dickinson said on Wednesday its board has authorized a plan to separate its life sciences unit as the medical device maker aims to focus on its core business.
Becton, Dickinson Non-GAAP EPS of $3.43 beats by $0.44, revenue of $5.17B beats by $60M
Becton, Dickinson (BDX) reports Q1 fiscal 2025 results: Non-GAAP EPS beats by $0.44, revenue beats by $60M, shares down 2.94%.
Becton Dickinson & Co Surpasses Q1 Expectations with $3.43 EPS and $5.2 Billion Revenue
Becton Dickinson & Co Surpasses Q1 Expectations with $3.43 EPS and $5.2 Billion Revenue
BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 s...
BD Reports First Quarter Fiscal 2025 Financial Results
Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organic GAAP and adjusted diluted EPS of $1.0...
Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit
Activist investor Starboard Value has taken a stake in Becton, Dickinson and Company (NYSE: BDX) and is pressing the $72 billion medical technology company to sell its life sciences division . The he...
Starboard Value pushes medical device maker Becton Dickinson to spin off unit
Activist investor takes stake in $72bn medical technology company in fund’s latest healthcare sector campaign
Cancer Diagnostics Market Size is Expected to Reach USD 178.26 Billion by 2033, Growing at a CAGR of 5.91%: Straits Research
New York, United States, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Cancer diagnostics is the process of identifying biomarkers, proteins, and other indicators that assist in identifying a cancerous tumor. Pla...
Becton Dickinson gains amid reports it's evaluating separating life sciences unit
Starboard Value pushes Becton Dickinson to sell life sciences unit, FT reports
Activist investor Starboard Value has taken a stake in Becton Dickinson and is pushing the medical technology company to sell its life sciences unit, the Financial Times reported on Monday.
Becton, Dickinson and Company (BDX) Announces Results of 2025 Annual Meeting
Becton, Dickinson and Company (BDX) Announces Results of 2025 Annual Meeting
Becton, Dickinson and Company to effect additional $10M share repurchase program
BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25
FRANKLIN LAKES, N.J. , Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has decla...
What Can The Dividend Kings Deliver In 2025?
The Dividend Kings underperformed the broad U.S. equity market in 2024, achieving a 5.53% total return compared to the S&P 500's 24.89%. 2024 returns for the Dividend Kings were primarily driven by ea...